Univest
Univest
  • Markets

3 Motorcycles Maker, Drug Ingredients Maker and Engines and Power Generators Maker Stocks With a Strong Future Roadmap: Hero MotoCorp, Laurus Labs and Cummins India

  • November 17, 2026
  • Posted by: Lakshit Sharma
  • Category: Best Stocks
No Comments
3 Motorcycles Maker, Drug Ingredients Maker and Engines and Power Generators Maker Stocks With a Strong Future Roadmap: Hero MotoCorp, Laurus Labs and Cummins India

Hero MotoCorp, Laurus Labs and Cummins India: ROE of 16.8% to 27.9% and FY22 to FY26 revenue CAGR of 8.5% to 18.5%. Prices as of 16 Nov 2026.

Quick Answer

The three motorcycle, drug ingredient and engine stocks to watch are Hero MotoCorp, Laurus Labs and Cummins India. Their return on equity ranges from 16.8% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 18.5%. Cummins India leads on both return on equity at 27.9% and revenue growth at 18.5% a year. Prices are based on the 16 November 2026 close, and this article is educational, not investment advice.

Motorcycle, drug ingredient and engine stocks give investors a way to track businesses that sit close to everyday demand in India. Hero MotoCorp, Laurus Labs and Cummins India cover a motorcycles maker, a drug ingredients maker and an engines and power generators maker.

This list covers three motorcycle, drug ingredient and engine stocks with complete current figures: Hero MotoCorp, Laurus Labs and Cummins India. Every figure comes from the latest reported financials and the 16 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Are Motorcycle, Drug Ingredient and Engine Stocks?
  • Motorcycle, Drug Ingredient and Engine Stocks at a Glance
  • Why Do Motorcycle, Drug Ingredient and Engine Stocks Have a Strong Roadmap in India?
  • Why Hero MotoCorp Features Among These Motorcycle, Drug Ingredient and Engine Stocks
  • Why Laurus Labs Features Among These Motorcycle, Drug Ingredient and Engine Stocks
  • Why Cummins India Features Among These Motorcycle, Drug Ingredient and Engine Stocks
  • Hero MotoCorp vs Laurus Labs vs Cummins India on Key Financials
  • Key Risks to Check Before Investing in Motorcycle, Drug Ingredient and Engine Stocks
  • Final Thoughts on Motorcycle, Drug Ingredient and Engine Stocks
    • What are motorcycle, drug ingredient and engine stocks?
    • Which motorcycle, drug ingredient and engine stocks are covered in this list?
    • Why do motorcycle, drug ingredient and engine stocks have a strong future roadmap in India?
    • How has Hero MotoCorp performed financially?
    • How has Laurus Labs performed financially?
    • How has Cummins India performed financially?
    • What risks should investors check before buying motorcycle, drug ingredient and engine stocks?
    • Is this list of motorcycle, drug ingredient and engine stocks investment advice?

What Are Motorcycle, Drug Ingredient and Engine Stocks?

Motorcycle, drug ingredient and engine stocks are listed companies that make commuter motorcycles and scooters for India, make active drug ingredients and finished medicines for global pharma firms, and make engines and power generators for industry and data centres. Their earnings depend on two wheeler demand, drug orders and backup power demand.

Motorcycle, Drug Ingredient and Engine Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
Hero MotoCorp 5,359.5 100,778 18.4 23.4 26.6 0.04
Laurus Labs 2,220 111,434 102.2 36.0 16.8 0.48
Cummins India 4,233 127,515 53.9 44.4 27.9 0.00

On valuation, Hero MotoCorp trades at a P/E below the industry P/E, while Laurus Labs and Cummins India trade above it, which reflects the growth the market already expects. Readers comparing motorcycle, drug ingredient and engine stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in motorcycle, drug ingredient and engine stocks can use the coming numbers to test whether growth is holding.

Why Do Motorcycle, Drug Ingredient and Engine Stocks Have a Strong Roadmap in India?

Motorcycle, drug ingredient and engine stocks have a strong roadmap in India because steady demand for two wheelers, rising outsourcing of drug making and strong demand for backup power keep widening the market for these companies.

  • Motorcycles. Riders choose trusted commuter brands.
  • Drug ingredients. Pharma firms source from reliable plants.
  • Engines and generators. Data centres and factories need backup power.

Why Hero MotoCorp Features Among These Motorcycle, Drug Ingredient and Engine Stocks

Among the motorcycle, drug ingredient and engine stocks on this list, Hero MotoCorp is one of the world’s largest two-wheeler makers by volume, selling motorcycles and scooters across India through a vast network of dealers and service points, and it also exports to several markets.

Revenue rose from Rs 30,106 crore in FY22 to Rs 48,469 crore in FY26, a compound annual growth rate of 12.6%. Net profit grew from Rs 2,329 crore in FY22 to Rs 5,776 crore in FY26, which works out to a compound annual growth rate of 25.5%.

In the June 2026 quarter, revenue grew 35.4% year on year to Rs 13,586 crore. The company has a return on equity of 26.6%, a debt to equity ratio of 0.04 and a market capitalisation of Rs 100,778 crore. The stock trades at a P/E of 18.4, below the industry P/E of 23.4.

Roadmap: The company is widening its premium motorcycle range, building an electric vehicle presence and growing its exports. Its large rural and semi-urban reach supports demand when household spending improves.

What to watch: Track monthly volumes, premium mix, electric vehicle progress and rural demand.

Why Laurus Labs Features Among These Motorcycle, Drug Ingredient and Engine Stocks

Among the two wheeler, API maker and power generator shares on this list, Laurus Labs is a Hyderabad-based pharmaceutical company with businesses in active ingredients, finished formulations, custom synthesis and biotechnology, with a leading position in anti-retroviral medicines.

In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%.

Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0.

Roadmap: The company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.

What to watch: Follow the ramp-up of new capacity in formulations and the order flow in custom synthesis.

Why Cummins India Features Among These Motorcycle, Drug Ingredient and Engine Stocks

Among the three companies on this list, Cummins India makes diesel and natural gas engines, generator sets, filtration products and power systems for infrastructure, data centres and industrial customers, and it also exports.

The company has a return on equity of 27.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 127,515 crore. The stock trades at a P/E of 53.9, above the industry P/E of 44.4.

Revenue rose from Rs 6,414 crore in FY22 to Rs 12,661 crore in FY26, a compound annual growth rate of 18.5%. Net profit grew from Rs 934 crore in FY22 to Rs 2,362 crore in FY26, which works out to a compound annual growth rate of 26.1%. In the June 2026 quarter, revenue grew 17.2% year on year to Rs 3,563 crore, while net profit rose 0.9% to Rs 609 crore.

Roadmap: The company benefits from demand for backup power at data centres, infrastructure projects and industrial plants, and it is widening its export base. A debt-free balance sheet supports capacity additions and new product lines.

What to watch: Track demand from data centres and new infrastructure and the growth of exports.

Hero MotoCorp vs Laurus Labs vs Cummins India on Key Financials

The table below sets the three motorcycle, drug ingredient and engine stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
Hero MotoCorp 30,106 48,469 12.6% 5,776 11.9%
Laurus Labs 4,951 6,868 8.5% 890 13.0%
Cummins India 6,414 12,661 18.5% 2,362 18.7%

Cummins India posts the highest return on equity in this group at 27.9%. Hero MotoCorp has the largest FY26 revenue at Rs 48,469 crore, and Cummins India shows the fastest revenue growth with a 18.5% compound annual rate. A useful habit with motorcycle, drug ingredient and engine stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Company Q1 FY26 Revenue (Rs Cr) Q1 FY27 Revenue (Rs Cr) Year-on-Year Growth
Hero MotoCorp 10,038 13,586 35.4%
Laurus Labs 1,580 2,035 28.8%
Cummins India 3,041 3,563 17.2%

Key Risks to Check Before Investing in Motorcycle, Drug Ingredient and Engine Stocks

Every theme carries risks that deserve a check before any decision. For these motorcycle, drug ingredient and engine stocks, the main points are: Long-term two wheeler, API maker and power generator shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

  • Demand cycles. Sales can vary with seasons and rates.
  • Regulatory approvals. Plant inspections and approvals can affect supplies.
  • Order timing. Project awards can shift between periods.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter motorcycle, drug ingredient and engine stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Motorcycle, Drug Ingredient and Engine Stocks

Motorcycle, drug ingredient and engine stocks work best when investors track growth, valuation and return on equity side by side. Hero MotoCorp, Laurus Labs and Cummins India each have a clear plan to grow. Based on the 16 November 2026 close, Hero MotoCorp trades at Rs 5,359.5, Laurus Labs at Rs 2,220 and Cummins India at Rs 4,233. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these motorcycle, drug ingredient and engine stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track motorcycle, drug ingredient and engine stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are motorcycle, drug ingredient and engine stocks?

Ans. Motorcycle, drug ingredient and engine stocks are listed companies that make commuter motorcycles and scooters for India, make active drug ingredients and finished medicines for global pharma firms, and make engines and power generators for industry and data centres. Their earnings depend on two wheeler demand, drug orders and backup power demand. This list looks at three of them, Hero MotoCorp, Laurus Labs and Cummins India, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.

Which motorcycle, drug ingredient and engine stocks are covered in this list?

Ans. This list covers Hero MotoCorp, Laurus Labs and Cummins India. Based on the 16 November 2026 close, Hero MotoCorp traded at Rs 5,359.5, Laurus Labs at Rs 2,220 and Cummins India at Rs 4,233. Their return on equity ranges from 16.8% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 18.5%.

Why do motorcycle, drug ingredient and engine stocks have a strong future roadmap in India?

Ans. Motorcycle, drug ingredient and engine stocks have a strong roadmap in India because steady demand for two wheelers, rising outsourcing of drug making and strong demand for backup power keep widening the market for these companies. The main drivers are as follows. Motorcycles. Riders choose trusted commuter brands. Drug ingredients. Pharma firms source from reliable plants. Engines and generators. Data centres and factories need backup power. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Hero MotoCorp performed financially?

Ans. Revenue rose from Rs 30,106 crore in FY22 to Rs 48,469 crore in FY26, a compound annual growth rate of 12.6%. Net profit grew from Rs 2,329 crore in FY22 to Rs 5,776 crore in FY26, which works out to a compound annual growth rate of 25.5%. In the June 2026 quarter, revenue grew 35.4% year on year to Rs 13,586 crore. The company has a return on equity of 26.6%, a debt to equity ratio of 0.04 and a market capitalisation of Rs 100,778 crore. The stock trades at a P/E of 18.4, below the industry P/E of 23.4. Looking ahead, the company is widening its premium motorcycle range, building an electric vehicle presence and growing its exports. Its large rural and semi-urban reach supports demand when household spending improves.

How has Laurus Labs performed financially?

Ans. Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0. Looking ahead, the company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.

How has Cummins India performed financially?

Ans. Revenue rose from Rs 6,414 crore in FY22 to Rs 12,661 crore in FY26, a compound annual growth rate of 18.5%. Net profit grew from Rs 934 crore in FY22 to Rs 2,362 crore in FY26, which works out to a compound annual growth rate of 26.1%. In the June 2026 quarter, revenue grew 17.2% year on year to Rs 3,563 crore, while net profit rose 0.9% to Rs 609 crore. The company has a return on equity of 27.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 127,515 crore. The stock trades at a P/E of 53.9, above the industry P/E of 44.4. Looking ahead, the company benefits from demand for backup power at data centres, infrastructure projects and industrial plants, and it is widening its export base. A debt-free balance sheet supports capacity additions and new product lines.

What risks should investors check before buying motorcycle, drug ingredient and engine stocks?

Ans. Investors should check a few risks before buying motorcycle, drug ingredient and engine stocks. Demand cycles. Sales can vary with seasons and rates. Regulatory approvals. Plant inspections and approvals can affect supplies. Order timing. Project awards can shift between periods. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of motorcycle, drug ingredient and engine stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.



API maker and power generator shares Best Stocks commuter bikes Cummins India drug ingredient and engine stocks Hero MotoCorp Laurus Labs motorcycle pharma ingredients and diesel engine stocks two wheeler

Leave a Reply Cancel reply